로딩 중…
지수 로딩 중…
HLB bioStep Co.,Ltd.
278650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,980+10.61%
2026-08-04
Financials
Valuation Metrics
HLB bioStep Co.,Ltd.'s Market Cap is ₩345B. At end of 2025 it was ₩1267B. Ranked #1981 of 2,436 in KR market (top 81%), #1246 of 1,649 on KOSDAQ (top 76%), #212 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 34.52B KRW | KR#1,981/2,436 Sec#212/234 |
| Revenue | 73.96B KRW | KR#1,572/2,436 Sec#102/234 |
| Net Income | -20.54B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 154.73B KRW | KR#1,454/2,436 Sec#114/234 |
| Net Assets | 100.94B KRW | KR#1,393/2,436 Sec#114/234 |
| Employees | 167 | KR#1,222/2,436 Sec#101/234 |
| Value | ||
| P/B | 0.34x | KR#415/2,436 Sec#13/234 |
| P/S | 0.47x | KR#879/2,436 Sec#34/234 |
| FCF Yield | 3.22% | KR#985/2,436 Sec#62/234 |
| Profitability | ||
| ROE | -20.35% | KR#2,082/2,436 Sec#164/234 |
| ROA | -13.27% | KR#2,148/2,436 Sec#169/234 |
| Op. Margin | -11.74% | KR#2,016/2,436 Sec#137/234 |
| Revenue Growth | -0.68% | KR#1,481/2,436 Sec#143/234 |
| Financial Health | ||
| Debt Ratio | 153.29% | KR#1,232/2,436 Sec#141/234 |
| Total Debt | 29.92B KRW | KR#1,193/2,436 Sec#94/234 |
| FCF | 1.11B KRW | KR#1,138/2,436 Sec#83/234 |
| Cash | 28.60B KRW | KR#1,032/2,436 Sec#68/234 |
| Current Ratio | 1.20x | KR#1,582/2,436 Sec#165/234 |
| Performance | ||
| 1Y Return | -70.67% | KR#2,349/2,436 Sec#224/234 |
| 1M Return | -31.61% | KR#2,374/2,436 Sec#232/234 |
| From 52W High | -80.40% | KR#2,355/2,436 Sec#221/234 |
| 1Y MDD | -80.97% | KR#2,314/2,436 Sec#218/234 |
| Trading | ||
| Volume | 60,305 shares | KR#1,236/2,436 Sec#122/234 |
| Foreign Own. | 3.76% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -1,108 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,027 KRW | KR#1,302/2,436 Sec#93/234 |
Company Info
동사는 2012년 설립된 비임상 CRO 전문기업으로 코스닥 상장 후 2024년 GLP 독성시험 전문기업 HLB바이오코드를 인수하여 종속회사로 편입함. 신약 후보물질의 유효성과 안전성 검증을 주력으로, HLB바이오코드 인수로 GLP 독성시험까지 원스톱 서비스 제공이 가능해짐. 질환동물 유발 및 관리 특화 기술력으로 중대동물 실험에서 독보적 지위 확보, HLB그룹과 AI 신약개발 플랫폼 구축 등 신사업을 추진하고 있음. HLB바이오스텝는 2012년에 설립되었으며 인천광역시 연수구에 본사를 두고 있습니다.